What is Sales and Marketing Strategy of Biocon Company?

For novel biologics and biosimilars in the US and EU, a specialized team engages directly with KOLs, hospital networks, and GPOs. This direct approach is critical for complex product education and building prescriber trust in competitive markets.

In diverse emerging markets, the company leverages in-country distributors and local marketing partners. This indirect channel efficiently navigates fragmented regulatory landscapes and complex distribution infrastructures.

This cornerstone partnership commercializes biosimilars across over 120 countries, providing immediate access to an established global commercial infrastructure. In 2024, it was a primary driver, contributing over 65% of Biocon Biologics's total revenue of approximately $1.2 billion.

Small molecules and APIs are sold via B2B long-term supply agreements with other pharmaceutical companies. The digital channel is vital for corporate branding and disseminating scientific content, supporting the overall target market of Biocon strategy.

The corporate identity is built on the powerful dual pillars of Innovation and Access. This professional, scientifically rigorous stance appeals to a global patient base and healthcare providers.

A clean, modern design and a tone of voice that is authoritative yet compassionate visually communicate its patient-centric brand identity across all corporate touchpoints and communications.

Its unique selling proposition is a vertically integrated model from development to commercialization. This structure guarantees quality and controls costs, offering a compelling value-based proposition.

In response to growing ESG focus, the company highlights its green manufacturing processes. This strengthens its positioning around sustainability and responsible corporate practices.

The 'Equal Science, Greater Access' campaign targeted oncology specialists with robust interchangeability data. It utilized a global digital roadshow with KOLs and targeted journal ads to establish the biosimilar as a first-choice treatment.

This ongoing campaign focuses on patient access stories and reducing the financial toxicity of cancer care. Leveraging partnerships with advocacy groups, it has generated over 50 million digital impressions, enhancing brand trust.

The bevacizumab campaign captured a 22% volume share in key markets within its first year. It also contributed to a 15% year-on-year growth for the company's oncology portfolio in FY 2024.

Biocon's marketing strategy for biosimilars hinges on three pillars: irrefutable scientific data, strategic partnerships with medical communities, and a powerful narrative of patient-centric value and access.